<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5877968-9894-4490-A8ED-983A3DDA1DC6"><gtr:id>B5877968-9894-4490-A8ED-983A3DDA1DC6</gtr:id><gtr:name>Farr Institute of Health Informatics Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/84915200-8B36-4D78-B908-BE6E8F42B272"><gtr:id>84915200-8B36-4D78-B908-BE6E8F42B272</gtr:id><gtr:name>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5877968-9894-4490-A8ED-983A3DDA1DC6"><gtr:id>B5877968-9894-4490-A8ED-983A3DDA1DC6</gtr:id><gtr:name>Farr Institute of Health Informatics Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84915200-8B36-4D78-B908-BE6E8F42B272"><gtr:id>84915200-8B36-4D78-B908-BE6E8F42B272</gtr:id><gtr:name>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/37FB8E20-BC59-4137-8265-D606690F9501"><gtr:id>37FB8E20-BC59-4137-8265-D606690F9501</gtr:id><gtr:firstName>Bryan</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13090"><gtr:id>1BCF1FB8-F4E6-408C-B35F-376C5E89BBA4</gtr:id><gtr:title>The Evaluation of blood pressure treatment stratified according to Central Aortic Systolic Pressure (CASP) in Young Hypertensive Patients - The TREAT CASP study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13090</gtr:grantReference><gtr:abstractText>High blood pressure (BP) is a leading cause of heart disease and strokes and the commonest chronic condition treated in primary care. In the UK, ~25% of all adults and 50% aged over 65yrs have high BP. NICE guidance recommends treatment when BP exceeds 160/100mmHg (called stage II hypertension). NICE also recommends treatment of lower pressures (140-159/90-99mmHg, i.e. stage I hypertension) in those with evidence of damage due to BP, those with diabetes and/or cardiovascular disease (CVD) or those calculated to be at higher risk. However, there is uncertainty what to do about treatment of younger people (aged 40yrs and under) with stage I hypertension because; i) younger people have rarely been included in clinical trials, ii) are unlikely to have developed CVD and iii) risk calculators do not apply to this younger age group. NICE has identified this group of over 1 million younger people as a key priority for research to better identify who would benefit from treatment. BP is routinely measured with a cuff wrapped around the arm and the assumption is made that pressure measured in the arm accurately reflects the pressure in the artery (aorta) close to the heart and the vital organs. We have developed a simple, non-invasive method to measure pressure in the aorta, next to the heart. This pressure is termed &amp;quot;central aortic systolic pressure&amp;quot; or CASP. Importantly, we have shown that pressure in the arm may not be an accurate measure of CASP, especially in younger people. Moreover, CASP is a better predictor of stress on the heart and may better predict stroke and CVD compared to BP measured in the arm. Our study will take place at the UCL vascular physiology unit and will recruit young men (aged 18-40 years) with stage I hypertension. We hypothesise that men with a low CASP (despite a high BP in the arm) actually have a normal BP, with no evidence of strain on the heart and do not need treatment. In contrast, those with a high CASP value will have early evidence of strain on the heart and arteries and will benefit from treatment. We will use MRI to sensitively measure the structure of the heart and the arteries. We will compare in men with high CASP, the effects of treatment for 1 year to lower BP versus no treatment, to see whether lowering CASP improves early heart and artery damage. Our study has no ethical issues as people recruited into the study would not normally receive treatment. We are well placed to conduct this study because of our experience in developing novel ways of measuring CASP, our experience in large clinical trials and in sensitive MRI measurements. The cost of our study is curtailed because of access to our research technology, including our research MRI scanner. Resources requested are to fund staff, clinical tests and consumables. Findings from our study may provide compelling evidence for a better way to stratify younger people with early hypertension who would benefit most from treatment and also avoid long-term treatment of those who would get no benefit.</gtr:abstractText><gtr:technicalSummary>Research design: This two-stage study incorporates a stage 1 screening study (n=500) to identify men with HIGH and LOW CASP values who will enter a Stage 2 randomized clinical trial (RCT) using a PROBE design (n=130), or an observational follow up study (n=65). Study population: Men aged 18-40 years with stage 1 hypertension (brachial blood pressure 140-159/90-99mmHg) not currently treated and without cardiovascular disease (CVD) or target organ damage. Exclusions include men with secondary hypertension, target organ damage, diabetes, significant arrhythmia. Planned Interventions: Stage 1 has no intervention. The Stage 2 RCT will compare no treatment (control intervention) versus BP lowering (active treatment) according to NICE treatment guidelines for people aged &amp;lt;55years, with titration to achieve a CASP value of &amp;lt;120mmHg and/or at least a 5mmHg reduction from baseline Proposed Outcome Measures:Primary outcome is the change in left ventricular mass index (LVMI) from baseline to study end (12 months), between treatments. Secondary outcomes are markers of cardiovascular damage measured by MRI including LV mass/volume ratio; CMR myocardial tissue tagging; interstitial fibrosis; aortic distensibility; carotid and aortic wall thickness. Albumin excretion rate and retinal photography comprise other outcomes. Assessment &amp;amp; Follow up: In Stage 1, brachial BP and CASP will be measured by CASPro (n=500) which combines a BP monitor with radial tonometry. At the end of Stage 1, 130 men with HIGH CASP and 65 men with LOW CASP values will undergo measurement of LVMI by MRI. In the RCT and observational follow-up (Stage 2), brachial BP and CASP will be monitored at scheduled, 3 monthly follow-up visits, with more frequent visits during titration for the active treatment group. LVMI and secondary outcomes will be measured by MRI after 12 months follow up for all Stage 2 groups. Proposed sample size: The Stage 2 RCT will compare treatment vs. no treatment in groups of 65 men from the HIGH CASP group. We anticipate a change in LVMI between treatments of 6.6 g/m2 based on published data from 4 treatment studies comprising 7 active treatment arms in 627 individuals, SD 10.9g/m2. Power calculations indicate a sample size of 58 people per treatment are required to show a difference in LVMI with 90% power at p=0.05. Statistical analysis: The primary analysis at the end of the Stage 2 will use a linear regression model to compare the change in LV mass from baseline to study end between treatments. A students? t-test will also be used at the end of Stage 1 to compare values for LV mass index between the HIGH and LOW CASP groups. Projected timetables: 500 men with stage 1 hypertension will be identified and screened in the first 18 months of the study (Stage 1). The expected recruitment rate is similar to that of our previous screening studies. A 1 year RCT and an observational follow-up study (Stage 2) will follow completion of Stage 1.</gtr:technicalSummary><gtr:fund><gtr:end>2016-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>415586</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Comprehensive Biomedical Research Centre</gtr:department><gtr:description>NIHR UCL Hospitals Biomedical Research Centre</gtr:description><gtr:id>49C8C94F-35F2-412C-8B88-FE1A4C80BAB2</gtr:id><gtr:impact>none so far - study just completed set up and about to start recruiting</gtr:impact><gtr:outcomeId>pVfZdQd964L-1</gtr:outcomeId><gtr:partnerContribution>support for a Clinician scientist who is working directly on the project but was only part funded from the original grant support - this additional support from the BRC has enabled him to focus full time on this project and related studies in experimental medicine</gtr:partnerContribution><gtr:piContribution>working with infrastructure within the BRC and CRF</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Practice Research Datalink (CPRD)</gtr:department><gtr:description>Clinical Practice Research Data link (CPRD)</gtr:description><gtr:id>4D85BDC9-2055-47EE-A1FB-31D586B90984</gtr:id><gtr:impact>899 potential study participants being invited to participate in the study</gtr:impact><gtr:outcomeId>mmoYRSz5N3i-1</gtr:outcomeId><gtr:partnerContribution>Screening GP data bases to identify suitable patients to be invited to participate in this study and liaising with the GP practices to send out letter - 899 potential participants identified already</gtr:partnerContribution><gtr:piContribution>Engaged with CPRD and obtained funding from NOCLOR to support CRPD assistance with recruitment</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Comprehensive Biomedical Research Centre</gtr:department><gtr:description>NIHR Wellcome UCL Hospitals CRF Director</gtr:description><gtr:id>88AB5C02-3D88-408B-B8F0-B39E588145A8</gtr:id><gtr:impact>CRF redesignated a NIHR CRF in the 2016 national competition and was awarded &amp;pound;6.5m</gtr:impact><gtr:outcomeId>byp4UX4tFVW-3</gtr:outcomeId><gtr:partnerContribution>Developed the collaboration above to increase the depth and efficiency of our experimental medicine research.
the BRC supports experimental medicine research in the UCL CRF and the LWENS.</gtr:partnerContribution><gtr:piContribution>In June 2013 I assumed the role as Director of the NIHR Wellcome UCL Hospitals CRF. We have developed a collaboration with the Leonard Wolfson Experimental Neurology Centre (LWENS) to share expertise and develop joint SOPs and governance procedures for research
I have led the development of a new CRF build for UCL Hospitals which was opened in 2016 and I then stepped down from the role as CRF Director to focus on my roles at NIHR UCLH/UCL BRC Director and Director of Research for UCLH</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>NIHR Wellcome UCL Hospitals CRF Director</gtr:description><gtr:id>7168C192-9325-4802-8E02-61C7243886A7</gtr:id><gtr:impact>CRF redesignated a NIHR CRF in the 2016 national competition and was awarded &amp;pound;6.5m</gtr:impact><gtr:outcomeId>byp4UX4tFVW-1</gtr:outcomeId><gtr:partnerContribution>Developed the collaboration above to increase the depth and efficiency of our experimental medicine research.
the BRC supports experimental medicine research in the UCL CRF and the LWENS.</gtr:partnerContribution><gtr:piContribution>In June 2013 I assumed the role as Director of the NIHR Wellcome UCL Hospitals CRF. We have developed a collaboration with the Leonard Wolfson Experimental Neurology Centre (LWENS) to share expertise and develop joint SOPs and governance procedures for research
I have led the development of a new CRF build for UCL Hospitals which was opened in 2016 and I then stepped down from the role as CRF Director to focus on my roles at NIHR UCLH/UCL BRC Director and Director of Research for UCLH</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leonard Wolfson Experimental Neurology Centre</gtr:department><gtr:description>NIHR Wellcome UCL Hospitals CRF Director</gtr:description><gtr:id>3F15D13A-4FAB-46EB-96E7-52D78D41D287</gtr:id><gtr:impact>CRF redesignated a NIHR CRF in the 2016 national competition and was awarded &amp;pound;6.5m</gtr:impact><gtr:outcomeId>byp4UX4tFVW-2</gtr:outcomeId><gtr:partnerContribution>Developed the collaboration above to increase the depth and efficiency of our experimental medicine research.
the BRC supports experimental medicine research in the UCL CRF and the LWENS.</gtr:partnerContribution><gtr:piContribution>In June 2013 I assumed the role as Director of the NIHR Wellcome UCL Hospitals CRF. We have developed a collaboration with the Leonard Wolfson Experimental Neurology Centre (LWENS) to share expertise and develop joint SOPs and governance procedures for research
I have led the development of a new CRF build for UCL Hospitals which was opened in 2016 and I then stepped down from the role as CRF Director to focus on my roles at NIHR UCLH/UCL BRC Director and Director of Research for UCLH</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Farr Institute of Health Informatics Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with the UCL Farr institute</gtr:description><gtr:id>DF228120-3D3E-461A-9581-FA6F8F0A8106</gtr:id><gtr:impact>There have been a number of publications emanating from the collaboration. The most significant output has been the establishment of a multidisciplinary research team embedded within the NHS to help drive data science at UCLH and via the NIHR HIC project</gtr:impact><gtr:outcomeId>58b71244415a35.22233305-1</gtr:outcomeId><gtr:partnerContribution>Major input on data science strategy and the development of our Health Informatics, Genomics, Omics and Data Science (HIGODS) cross cutting theme for our successful BRC application in 2016 which I led. Prof Harry Hemingway the UCL Farr Director is now the BRC HIGODS theme director which has led to even greater collaboration and working.
For the TREAT CASP study we have used the UCL data safe haven embedded within the Farr institute</gtr:partnerContribution><gtr:piContribution>Developing data science infrastructure strategy for the BRC renewal bid and to ensure closer collaboration with the NHS via UCLH
This has also been instrumental in the success of our contribution to the NIHR Health Informatics Collaborative 
My contributions been leadership via the BRC and research and clinical expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>New Method to Measure Aortic Pressure - BBC TV</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>77506092-73A1-46EB-B099-E319EE2D1938</gtr:id><gtr:impact>reported a new method to estimate aortic pressure - could revolutionise future BP measurement 
received major BBC news coverage

major BBC new coverage</gtr:impact><gtr:outcomeId>mtA9f9ndDyh</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-12518633</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC News</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0587FD24-043A-4BCC-BA6A-3B0FF3BB6A01</gtr:id><gtr:impact>major story on BBC news about our research - see link below
many enquiries from the public which i have replied to
the technology we have developed and cited in this report on BBC is now being used in patient assessment in the NHS and in our research

see above
also had enquiries from Apple and Samsung about business collaboration related to this technology</gtr:impact><gtr:outcomeId>JVdjehZUqju</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-22812477</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR UCL Hospitals BRC Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>96D31277-1903-4198-8A3A-91194BC4C95D</gtr:id><gtr:impact>As BRC Director I Developed a BRC newsletter for communication to the UCL and UCLH community about the work of the BRC

wider and better engagement with the BRC</gtr:impact><gtr:outcomeId>TNjGjSxogw7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.uclhospitals.brc.nihr.ac.uk</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Development of the UCL Hospitals Research Gateway</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>05F0C5DE-9444-4B7C-A502-EF6054EDD23B</gtr:id><gtr:impact>An online gateway highlighting the research opportunities for members of the general public linked to their disease of interest

Mutliple website hits and enquiries about participation in studies from the general public who had never previously engaged with research</gtr:impact><gtr:outcomeId>54647972603d74.99953675</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.uclhospitals.brc.nihr.ac.uk/news/uclh-research-gateway-launches</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Hospitals Research Open day for the general public</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4D0BB3C5-FB12-4E78-ACD2-45CBD78C5AFE</gtr:id><gtr:impact>Excellent feedback from the general public and schools who attended and major interest in participation in our research project - led to increased recruitment

A number of schools asking if they could attend next year</gtr:impact><gtr:outcomeId>54647894976493.88243406</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>111500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>NIHR BRC competition 3 - Resdesignation and new funding award to NIHR University College Hospitals Biomedical Research Centre - Director</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B43FC8A6-15C6-4C7F-843E-15880AEBE893</gtr:id><gtr:outcomeId>58b85920842253.40369917</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>NIH University College London Hospitals Clinical Research Facility - Co-applicant</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1CB1B2D5-8D8B-4C04-B471-6F4C16F21742</gtr:id><gtr:outcomeId>58b85a69dafa49.88624600</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Heart Foundation Special programme Grant</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>TIME study - Treatment In the Morning versus Evening (TIME) BHF CS/14/1/30659</gtr:fundingRef><gtr:id>C30AF072-5A8D-4E79-9D76-F59A194D346A</gtr:id><gtr:outcomeId>54648257cce924.11130967</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE Hypertension Guidelines Chairman</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B9106D81-AFC2-4235-96AE-8279586155F8</gtr:id><gtr:impact>Guideline published paper in Lancet confirming that the changes in practice would lead to changes in efficiency and cost effectiveness of diagnosis of hypertension which affects 25% of the adult population
Recent Lancet paper - May 2014 has demonstrated the impact of the NICRE hypertension guidance in improving BP control in the UK which should translate into improvements in cardiovascular health</gtr:impact><gtr:outcomeId>jPKGrXPxcss</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://www.nice.org.uk/guidance/cg127</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>devices currently marketed.
we have developed a partnership between UCL Business and Healthstats UK</gtr:description><gtr:id>A11A34F2-1132-48A6-AD61-91A5A9136F5A</gtr:id><gtr:impact>I won the Times Higher Award for outstanding contribution to innovation and technology 2011
URL:http://www2.le.ac.uk/offices/press/press-releases/2011/november/university-of-leicester-wins-national-award-for-outstanding-contribution-to-innovation-and-technology-1</gtr:impact><gtr:outcomeId>QSCPPHrxXp7</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>methods to measure aortic pressure</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Using MRI physics to model aortic haemodynamics in relation to the evaluation of patients recruited into our TREAT CASP study
We anticipate that this model will be an advance on current methods that could ultimately be applied in clinical assessment of patients in the NHS once the validation is complete</gtr:description><gtr:id>D6009339-3145-4655-B9BD-113D942E0C7B</gtr:id><gtr:impact>Still in development</gtr:impact><gtr:outcomeId>54647bb4e3c588.84546887</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Developing methods to assess aortic function and flow using MRI</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>developed a novel method to measure aortic pressure from the radial pulse wave. this meted has been commercialised and is now widely used in research. the method has been adopted as a US FDA standard for central aortic pressure measurement</gtr:description><gtr:id>49001578-B619-4A64-A7CA-2DDEDC9A1D57</gtr:id><gtr:impact>research grant to my group from NIHR EME/MRC to evaluate its use in better stratification of treatment decisions for young people with hypertension.
used by Novartis Pharma in evaluating new drug efficacy in clinical trials</gtr:impact><gtr:outcomeId>h5nh4vaWghh</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Development of new methods to measure central aortic pressure</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://www.healthstats.com/index3.php</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C2AABBC9-2F83-46AE-927E-C233F8834141</gtr:id><gtr:title>Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/698193b173cb0d9b16b5497932c83565"><gtr:id>698193b173cb0d9b16b5497932c83565</gtr:id><gtr:otherNames>B?hm M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>58b70d4e6ec849.85068006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9117E2E5-4898-4848-A0C7-20ADC20928B1</gtr:id><gtr:title>Expertise: No Longer a Sine Qua Non for Guideline Authors?</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3efb71d61e7d20b4d24266cc10f460ea"><gtr:id>3efb71d61e7d20b4d24266cc10f460ea</gtr:id><gtr:otherNames>Messerli FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa8eb5ed395b0.43878058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAD98382-D16C-4927-81AF-9A58B6395514</gtr:id><gtr:title>Predicting Out-of-Office Blood Pressure in the Clinic for the Diagnosis of Hypertension in Primary Care: An Economic Evaluation.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84bc009f26815e77f7dec23d47a43394"><gtr:id>84bc009f26815e77f7dec23d47a43394</gtr:id><gtr:otherNames>Monahan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa8eb61e22e99.00421071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA3E9E3E-FB51-4751-9CF7-7BFC820FB033</gtr:id><gtr:title>Effects of exercise on central aortic pressure before and after treatment with renin-angiotensin system blockade in patients with hypertension.</gtr:title><gtr:parentPublicationTitle>Journal of the renin-angiotensin-aldosterone system : JRAAS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1be90d3980977906349ead45f11ff12b"><gtr:id>1be90d3980977906349ead45f11ff12b</gtr:id><gtr:otherNames>Lacy PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-3203</gtr:issn><gtr:outcomeId>546390689ca324.27456051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC3E7F5C-9C8E-405C-B53F-EDD6908F490B</gtr:id><gtr:title>Drug discovery in renin-angiotensin system intervention: past and future.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in cardiovascular disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1753-9447</gtr:issn><gtr:outcomeId>58b70d4d4a7632.54854508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C31894-07CE-4B92-9C47-92587108B78A</gtr:id><gtr:title>4A.01: LONG-TERM EFFECTS OF RENAL ARTERY DENERVATION IN REAL WORLD PATIENTS WITH UNCONTROLLED HYPERTENSION FROM THE GLOBAL SYMPLICITY REGISTRY.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/609f27a6069c218e75d993a26a7249b1"><gtr:id>609f27a6069c218e75d993a26a7249b1</gtr:id><gtr:otherNames>Mancia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>56e0012bbe7a41.82569244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0E9750B-B6F0-478B-8C50-F565D8F1CAC0</gtr:id><gtr:title>Comparison of wrist-type and arm-type 24-h blood pressure monitoring devices for ambulatory use.</gtr:title><gtr:parentPublicationTitle>Blood pressure monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3573a3e1fffaace084a05fbde32658"><gtr:id>bb3573a3e1fffaace084a05fbde32658</gtr:id><gtr:otherNames>Komori T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-5237</gtr:issn><gtr:outcomeId>pm_23638_28_23263536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE45100F-2108-4827-AB48-50D6B9CEE1E0</gtr:id><gtr:title>Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beaf27e496240fb4fa70c97efa676215"><gtr:id>beaf27e496240fb4fa70c97efa676215</gtr:id><gtr:otherNames>van Steen SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>5aa8ec0d9ecf57.86543186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C1282DA-F0FA-47EF-8253-806D3CA85A7F</gtr:id><gtr:title>Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMC cardiovascular disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96fcd9717fb71dc9e0bb9c04a09b0e90"><gtr:id>96fcd9717fb71dc9e0bb9c04a09b0e90</gtr:id><gtr:otherNames>O'Brien C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2261</gtr:issn><gtr:outcomeId>pm_23638_28_23522245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D783145D-A281-4300-A8CF-1E8324ED8128</gtr:id><gtr:title>Associations between body mass index and the risk of renal events in patients with type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Nutrition &amp; diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75614a77d5f56c81295b3fdb0760d656"><gtr:id>75614a77d5f56c81295b3fdb0760d656</gtr:id><gtr:otherNames>Mohammedi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2044-4052</gtr:issn><gtr:outcomeId>5aa8ec0e018b95.45493355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA006E66-C281-47CD-835C-5209F0504371</gtr:id><gtr:title>High prevalence of masked uncontrolled hypertension in people with treated hypertension.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38e1b7e160b80086571eedcb82f2c23"><gtr:id>a38e1b7e160b80086571eedcb82f2c23</gtr:id><gtr:otherNames>Banegas JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5463906772afd8.95149412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFCA12F5-5EBB-4980-A21C-8AD77E5B5C86</gtr:id><gtr:title>Circulating bone morphogenetic protein-7 and transforming growth factor-?1 are better predictors of renal end points in patients with type 2 diabetes mellitus.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afd040205fdd3ea13c0be02839fcb011"><gtr:id>afd040205fdd3ea13c0be02839fcb011</gtr:id><gtr:otherNames>Wong MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_23638_28_23235570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA1F79EA-D048-4554-BEC9-EDE3895202E3</gtr:id><gtr:title>Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc56a9ab2b90060389c3f2a64e3baf9c"><gtr:id>fc56a9ab2b90060389c3f2a64e3baf9c</gtr:id><gtr:otherNames>Linz D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>58b70dea71bde1.90810799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7441310C-0A7C-498F-91AF-F0993212237B</gtr:id><gtr:title>Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb40fdb10053cd115185bcbdcfe5848e"><gtr:id>eb40fdb10053cd115185bcbdcfe5848e</gtr:id><gtr:otherNames>Penaloza-Ramos MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn><gtr:outcomeId>56e0012c6ddbe5.90922204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE43B0DA-22C3-41F0-B674-8138FC8244FE</gtr:id><gtr:title>Hypertension - a clinical update for physicians.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a86f916c01e461a4a0f547f31865aec"><gtr:id>3a86f916c01e461a4a0f547f31865aec</gtr:id><gtr:otherNames>Musameh MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>pm_23638_28_23681869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B97DFFD-14F5-4F13-A541-ECB82C3ADE2B</gtr:id><gtr:title>Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cee6c099c3d7654c71c9da4ae3e6f515"><gtr:id>cee6c099c3d7654c71c9da4ae3e6f515</gtr:id><gtr:otherNames>Parati G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5aa8ec0e8b7652.13353761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C5A06AB-9C58-47D8-8F69-11F8677AE862</gtr:id><gtr:title>Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80938f9b62df59a9d74aaed92a6fe249"><gtr:id>80938f9b62df59a9d74aaed92a6fe249</gtr:id><gtr:otherNames>Spiering W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5aa8eb5d495ea4.44956345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54AC994E-14EC-498D-B804-9363985655F6</gtr:id><gtr:title>Erratum. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295-303.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7b9a232b4a459045a9915552f28c9b"><gtr:id>ba7b9a232b4a459045a9915552f28c9b</gtr:id><gtr:otherNames>Hillis GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>56e0012b97a217.53651013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D4DC463-6655-4E71-83E4-21A9CD56F1B0</gtr:id><gtr:title>Post-carotid Endarterectomy Hypertension. Part 2: Association with Peri-operative Clinical, Anaesthetic, and Transcranial Doppler Derived Parameters.</gtr:title><gtr:parentPublicationTitle>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f616e5027de659192e8e670fe4cffdd"><gtr:id>7f616e5027de659192e8e670fe4cffdd</gtr:id><gtr:otherNames>Newman JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-5884</gtr:issn><gtr:outcomeId>5aa8eb5ddfd720.62571906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1869E3CD-D399-4284-ABAB-FB6E713CDD76</gtr:id><gtr:title>Performance and persistence of a blood pressure self-management intervention: telemonitoring and self-management in hypertension (TASMINH2) trial.</gtr:title><gtr:parentPublicationTitle>Journal of human hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f831070612ab8f0f1c018947a9a0418a"><gtr:id>f831070612ab8f0f1c018947a9a0418a</gtr:id><gtr:otherNames>Bray EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9240</gtr:issn><gtr:outcomeId>56e0012b683993.51210534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED77D165-4430-405F-ACED-ED43A811E625</gtr:id><gtr:title>Blood pressure and diabetes: a fatal attraction.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>pm_23638_28_24092247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>065F6EFC-B6DF-4612-AA57-C7955F859E72</gtr:id><gtr:title>Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The Ambulatory Central Aortic Pressure (AmCAP) Study.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_23638_28_23630950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DF4A60D-F27A-4695-93B5-46A54950612E</gtr:id><gtr:title>Time to Abandon Clinic Blood Pressure for the Diagnosis of Hypertension?</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>58b70d4e3d04c5.13668881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A35214C3-0C64-4E98-B754-F3D7BE6D8C35</gtr:id><gtr:title>24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>Cardiovascular diabetology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92a781fcb81a82912c57ec106d0995f"><gtr:id>c92a781fcb81a82912c57ec106d0995f</gtr:id><gtr:otherNames>Theilade S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1475-2840</gtr:issn><gtr:outcomeId>pm_23638_28_23978271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23BE113A-7E93-4CEA-B22A-A66D472FB53F</gtr:id><gtr:title>Vascular ageing and interventions: lessons and learnings.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in cardiovascular disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1753-9447</gtr:issn><gtr:outcomeId>58b70d4d0f3d40.47276836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CD298A1-A56A-4FE3-95E3-98B50970BE5B</gtr:id><gtr:title>Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/905ff43618ea4b3ff093501a6b8e4e19"><gtr:id>905ff43618ea4b3ff093501a6b8e4e19</gtr:id><gtr:otherNames>Hirakawa Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>58b70d4eebc648.61713499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC6F9163-72F8-4148-91EB-6B71B8EDB4C4</gtr:id><gtr:title>A role for mitochondrial oxidants in stress-induced premature senescence of human vascular smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>Redox biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f92959430ff9f0d2c5b1c196b538791"><gtr:id>5f92959430ff9f0d2c5b1c196b538791</gtr:id><gtr:otherNames>Mistry Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-2317</gtr:issn><gtr:outcomeId>pm_23638_28_24191234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4525048-88C5-48FC-B0A3-B9AC2EE47029</gtr:id><gtr:title>PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b70d4eaa7d04.80596039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79366CBB-C5B5-41A9-9EC5-CB183306C348</gtr:id><gtr:title>Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7a694cc07e18946e7986ae4edbbde89"><gtr:id>f7a694cc07e18946e7986ae4edbbde89</gtr:id><gtr:otherNames>Jun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>5aa8eb62223612.46573264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A9DD9F4-0EBC-4693-816A-7AE80EBAA026</gtr:id><gtr:title>Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation.</gtr:title><gtr:parentPublicationTitle>Journal of human hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d8b06617486d4669e1ef29358e24b5c"><gtr:id>6d8b06617486d4669e1ef29358e24b5c</gtr:id><gtr:otherNames>Patel P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9240</gtr:issn><gtr:outcomeId>56e0012c8f0b01.79095772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>872B2B1E-4BB3-4188-9986-129D6952F606</gtr:id><gtr:title>8B.04: RENAL ARTERY DENERVATION FOR TREATMENT OF HYPERTENSIVE PATIENTS WITH OR WITHOUT OBSTRUCTIVE SLEEP APNEA AND RESISTANT HYPERTENSION: RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/600efc5bf34315ae435014ef6968adf8"><gtr:id>600efc5bf34315ae435014ef6968adf8</gtr:id><gtr:otherNames>Mahfoud F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>56e0012be39bc0.50478914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53A775C8-3656-40EA-AFCD-30509CAFC72B</gtr:id><gtr:title>The impact of level of education on vascular events and mortality in patients with type 2 diabetes mellitus: Results from the ADVANCE study.</gtr:title><gtr:parentPublicationTitle>Diabetes research and clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/382e422a1d2761da4d42ec5647af6878"><gtr:id>382e422a1d2761da4d42ec5647af6878</gtr:id><gtr:otherNames>Blomster JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8227</gtr:issn><gtr:outcomeId>5aa8eb5fbab667.32410659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F69528CF-47E1-43ED-818D-812BDD759D09</gtr:id><gtr:title>How to Screen for Non-Adherence to Antihypertensive Therapy.</gtr:title><gtr:parentPublicationTitle>Current hypertension reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1425b0dfc4afb437765b9d6949ce827"><gtr:id>a1425b0dfc4afb437765b9d6949ce827</gtr:id><gtr:otherNames>Gupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1522-6417</gtr:issn><gtr:outcomeId>58b70d4e057291.31365488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D84B0CFF-37BA-48E0-B77D-CDDDFC71E095</gtr:id><gtr:title>Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccf342f8f7dfd363b89a2f96f567243b"><gtr:id>ccf342f8f7dfd363b89a2f96f567243b</gtr:id><gtr:otherNames>Zoungas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>5463906923df05.64142335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59DA85CC-3248-4165-814E-426521B0E132</gtr:id><gtr:title>Risk Factors for Nonadherence to Antihypertensive Treatment.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1425b0dfc4afb437765b9d6949ce827"><gtr:id>a1425b0dfc4afb437765b9d6949ce827</gtr:id><gtr:otherNames>Gupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa8eb5f4f0cc9.46190996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2AF688D-345F-4D23-B807-E98C6AF736B7</gtr:id><gtr:title>The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/382e422a1d2761da4d42ec5647af6878"><gtr:id>382e422a1d2761da4d42ec5647af6878</gtr:id><gtr:otherNames>Blomster JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>54639067a2a9b4.09827682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E39DF00B-8544-4276-B926-7537129399EE</gtr:id><gtr:title>Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>546390674ebc44.36830883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>749C8520-9ACD-4824-98AA-8ED0D0E26900</gtr:id><gtr:title>Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62669b53e98481724294af0f7a2ae396"><gtr:id>62669b53e98481724294af0f7a2ae396</gtr:id><gtr:otherNames>Singh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5aa8eb61a17452.85671026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D69A477F-2B72-4DB3-AF12-17B20ED5541B</gtr:id><gtr:title>Reply.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3efb71d61e7d20b4d24266cc10f460ea"><gtr:id>3efb71d61e7d20b4d24266cc10f460ea</gtr:id><gtr:otherNames>Messerli FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>5aa8eb5fe76461.34426787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEEF6504-B398-4810-868F-B26D565B2B9B</gtr:id><gtr:title>Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dae70f2356c097583763b3816f6b0fd1"><gtr:id>dae70f2356c097583763b3816f6b0fd1</gtr:id><gtr:otherNames>Perrone-Filardi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>5aa8eb60d4ec23.72403580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5506E844-D86E-4187-99DF-D6F05A7FDBF4</gtr:id><gtr:title>Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci&amp;oacute;n Card&amp;iacute;aca y Electrofisiolog&amp;iacute;a (SOLEACE).</gtr:title><gtr:parentPublicationTitle>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb84f4ac18942d2d2008bdc3eaef089f"><gtr:id>cb84f4ac18942d2d2008bdc3eaef089f</gtr:id><gtr:otherNames>Lip GYH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1099-5129</gtr:issn><gtr:outcomeId>5aa8eb6173c4f4.26866957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BABA5B9-3B13-4E55-BAF4-7C3141432370</gtr:id><gtr:title>Aortic augmentation index in endurance athletes: a role for cardiorespiratory fitness.</gtr:title><gtr:parentPublicationTitle>European journal of applied physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c7ff9cdb30e704b21c7266bd0e983ec"><gtr:id>6c7ff9cdb30e704b21c7266bd0e983ec</gtr:id><gtr:otherNames>Denham J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1439-6319</gtr:issn><gtr:outcomeId>58b70d4ccff332.79606288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F40A957-E855-433D-A958-A1CA1E61AD9F</gtr:id><gtr:title>Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Cardiovascular diabetology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75614a77d5f56c81295b3fdb0760d656"><gtr:id>75614a77d5f56c81295b3fdb0760d656</gtr:id><gtr:otherNames>Mohammedi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1475-2840</gtr:issn><gtr:outcomeId>5aa8eb627ca0c6.76103394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE9F5F1D-5FE5-40FA-9D23-C03179D91168</gtr:id><gtr:title>Predicting Out-of-Office Blood Pressure in the Clinic (PROOF-BP): Derivation and Validation of a Tool to Improve the Accuracy of Blood Pressure Measurement in Clinical Practice.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a677a3fda6071a31fa32e91b7008817"><gtr:id>9a677a3fda6071a31fa32e91b7008817</gtr:id><gtr:otherNames>Sheppard JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>58b70d4dbda576.93107348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9AA934D-0F78-482C-B091-D7B4C11E1F8D</gtr:id><gtr:title>Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4e3f25f1f5683af5f1cbb94527cfcaa"><gtr:id>c4e3f25f1f5683af5f1cbb94527cfcaa</gtr:id><gtr:otherNames>Chalmers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>pm_23638_28_24324048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAA1F862-DE52-46D4-B271-F978CE84D7EA</gtr:id><gtr:title>Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75614a77d5f56c81295b3fdb0760d656"><gtr:id>75614a77d5f56c81295b3fdb0760d656</gtr:id><gtr:otherNames>Mohammedi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>58b70d4ca4c7a3.21114187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>140A934C-CC43-4C7C-928D-CB6AD1B18C56</gtr:id><gtr:title>Has the SPRINT trial introduced a new blood-pressure goal in hypertension?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b880a7e397f5200ca64759292fda432c"><gtr:id>b880a7e397f5200ca64759292fda432c</gtr:id><gtr:otherNames>Ruiz-Hurtado G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5002</gtr:issn><gtr:outcomeId>5aa8eb5ea02172.47322119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C0260C0-F4AC-4AA9-8DAA-7DF67A14702C</gtr:id><gtr:title>Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c769f21bde2eebf29268e38823d6d64a"><gtr:id>c769f21bde2eebf29268e38823d6d64a</gtr:id><gtr:otherNames>McManus RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>54639068ea38e0.17462925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3923326-0BBB-432B-A2A5-3BAFEE8D02B8</gtr:id><gtr:title>Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccf342f8f7dfd363b89a2f96f567243b"><gtr:id>ccf342f8f7dfd363b89a2f96f567243b</gtr:id><gtr:otherNames>Zoungas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>546390694a2e20.07312500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6696E70C-615F-4E85-97A9-8462A40B58A7</gtr:id><gtr:title>Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3).</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d1d70604c294eac0e2a8352954d7196"><gtr:id>4d1d70604c294eac0e2a8352954d7196</gtr:id><gtr:otherNames>JBS3 Board</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>54639067ca8084.59018618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA3F3D3D-DE64-4889-9B58-15ADC1D888EB</gtr:id><gtr:title>Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8863dbb4a5cd67ad1aaa3fd8259bffb6"><gtr:id>8863dbb4a5cd67ad1aaa3fd8259bffb6</gtr:id><gtr:otherNames>Welsh P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>546390684fb722.89020064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F35B5DC-6503-42C2-915B-B759F920B366</gtr:id><gtr:title>The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7b9a232b4a459045a9915552f28c9b"><gtr:id>ba7b9a232b4a459045a9915552f28c9b</gtr:id><gtr:otherNames>Hillis GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>pm_23638_28_24089534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CDBF01F-384C-41E4-8992-BEE2A5B9101A</gtr:id><gtr:title>Clinic Versus Daytime Ambulatory Blood Pressure Difference in Hypertensive Patients: The Impact of Age and Clinic Blood Pressure.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38e1b7e160b80086571eedcb82f2c23"><gtr:id>a38e1b7e160b80086571eedcb82f2c23</gtr:id><gtr:otherNames>Banegas JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>58b70d4f32a8b4.43214997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9EDD07B-38F1-4880-BA4E-3F285FBBC6BD</gtr:id><gtr:title>Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afd040205fdd3ea13c0be02839fcb011"><gtr:id>afd040205fdd3ea13c0be02839fcb011</gtr:id><gtr:otherNames>Wong MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>58b70d4d8a9c49.71122298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA0E99ED-AF05-43C0-AA38-7C8477D3A97B</gtr:id><gtr:title>Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1&amp;middot;25 million people.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f620fe51d4a8878fc48d55995253fe2f"><gtr:id>f620fe51d4a8878fc48d55995253fe2f</gtr:id><gtr:otherNames>Rapsomaniki E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5463906873c485.52624588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54AD0441-CED5-43C8-A164-5B3CE3930CBB</gtr:id><gtr:title>Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3502725cf277359c3a848e7afabe4e24"><gtr:id>3502725cf277359c3a848e7afabe4e24</gtr:id><gtr:otherNames>Picone DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>5aa8eb6143fa54.47049329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DE936BA-6154-4D74-A9A0-FF970EFCE8C0</gtr:id><gtr:title>Excess pressure integral predicts cardiovascular events independent of other risk factors in the conduit artery functional evaluation substudy of Anglo-Scandinavian Cardiac Outcomes Trial.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19312f34fab8c4b94994c79b8e4c4db5"><gtr:id>19312f34fab8c4b94994c79b8e4c4db5</gtr:id><gtr:otherNames>Davies JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>546390682106c5.17276863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD28CB14-338A-43D8-AFF5-8D92FD635D90</gtr:id><gtr:title>Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5754e8047038db43afa0c99280b06cd1"><gtr:id>5754e8047038db43afa0c99280b06cd1</gtr:id><gtr:otherNames>Hata J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_23638_28_23926207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A2F17CF-58BA-4EEB-930A-A3A57E2E4B15</gtr:id><gtr:title>Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1425b0dfc4afb437765b9d6949ce827"><gtr:id>a1425b0dfc4afb437765b9d6949ce827</gtr:id><gtr:otherNames>Gupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa8eb5d84c945.55811610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC667348-0F1D-4633-B34F-F1D22ACA6B1C</gtr:id><gtr:title>Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>58b70dea31cc48.98590739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E5885DC-2716-473C-8832-BC6F64AD2465</gtr:id><gtr:title>Predicting out-of-office blood pressure level using repeated measurements in the clinic: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a677a3fda6071a31fa32e91b7008817"><gtr:id>9a677a3fda6071a31fa32e91b7008817</gtr:id><gtr:otherNames>Sheppard JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>54639068c53640.75369922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>606267E3-967A-4350-BEE8-8BE20254965A</gtr:id><gtr:title>Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.</gtr:title><gtr:parentPublicationTitle>Journal of the renin-angiotensin-aldosterone system : JRAAS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-3203</gtr:issn><gtr:outcomeId>pm_23638_28_22859712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97E62A1D-EF76-4A5E-83C8-4BF5AFE2FC6A</gtr:id><gtr:title>Post-Carotid Endarterectomy Hypertension. Part 1: Association with Pre-operative Clinical, Imaging, and Physiological Parameters.</gtr:title><gtr:parentPublicationTitle>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f616e5027de659192e8e670fe4cffdd"><gtr:id>7f616e5027de659192e8e670fe4cffdd</gtr:id><gtr:otherNames>Newman JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-5884</gtr:issn><gtr:outcomeId>5aa8eb5e3c66b4.74544983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BED5B117-CB8C-4DCB-B042-96B8BCA4D548</gtr:id><gtr:title>Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c75fd55e14acdc28b6018a37889c24"><gtr:id>11c75fd55e14acdc28b6018a37889c24</gtr:id><gtr:otherNames>Brown MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>56e0012c3f1da6.83807107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCC35249-41B4-4ADD-925E-E3790F04B384</gtr:id><gtr:title>Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/600efc5bf34315ae435014ef6968adf8"><gtr:id>600efc5bf34315ae435014ef6968adf8</gtr:id><gtr:otherNames>Mahfoud F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>pm_23638_28_23620497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B57CFBD9-DB9F-485C-967E-578DA923C083</gtr:id><gtr:title>Updated national and international hypertension guidelines: a review of current recommendations.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e3b1d6dfe973511b8278a99e8e536fc"><gtr:id>8e3b1d6dfe973511b8278a99e8e536fc</gtr:id><gtr:otherNames>Kjeldsen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>546390697aaaa3.11349431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4994B80F-9D4D-4875-9777-FA02B14496F8</gtr:id><gtr:title>Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.</gtr:title><gtr:parentPublicationTitle>Journal of the American Heart Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf8d5efc3393ef9a13e625223ce098ec"><gtr:id>bf8d5efc3393ef9a13e625223ce098ec</gtr:id><gtr:otherNames>MacDonald TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-9980</gtr:issn><gtr:outcomeId>5aa8eb624ecb98.63004174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D5868B4-5A38-45A9-9788-82CAA9E0C9F5</gtr:id><gtr:title>Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de500b5b867e2c94d5a1ac3508b5a2f9"><gtr:id>de500b5b867e2c94d5a1ac3508b5a2f9</gtr:id><gtr:otherNames>Alshehry ZH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>58b70d4c6da9b6.10994177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DEC7304-4151-44F1-83A4-03CD0B00B517</gtr:id><gtr:title>Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a791d09c9d1ba0b6172fb95affc03e5e"><gtr:id>a791d09c9d1ba0b6172fb95affc03e5e</gtr:id><gtr:otherNames>Nicholls SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>pm_23638_28_23999933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2103CF9-4DB4-4FC6-85CD-C74349D02359</gtr:id><gtr:title>Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62669b53e98481724294af0f7a2ae396"><gtr:id>62669b53e98481724294af0f7a2ae396</gtr:id><gtr:otherNames>Singh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>546390672912e7.81571068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C58FCAC9-5B66-4391-AAD6-DB2AD13A6F38</gtr:id><gtr:title>Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH).</gtr:title><gtr:parentPublicationTitle>European heart journal cardiovascular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dae70f2356c097583763b3816f6b0fd1"><gtr:id>dae70f2356c097583763b3816f6b0fd1</gtr:id><gtr:otherNames>Perrone-Filardi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-2404</gtr:issn><gtr:outcomeId>5aa8eb60a390a3.34769290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BAF0458-7098-4248-A3F2-A3A5B8D8348C</gtr:id><gtr:title>Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65a10b26a6d861966686dd87a21581b3"><gtr:id>65a10b26a6d861966686dd87a21581b3</gtr:id><gtr:otherNames>Atkins ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>58b70deab16297.92557933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6E01348-D6F8-4884-B433-74F86ADDDC09</gtr:id><gtr:title>Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry.</gtr:title><gtr:parentPublicationTitle>EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/698193b173cb0d9b16b5497932c83565"><gtr:id>698193b173cb0d9b16b5497932c83565</gtr:id><gtr:otherNames>B?hm M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1774-024X</gtr:issn><gtr:outcomeId>pm_23638_28_23965354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E112D943-7CCC-438B-9F4E-D58B6B2FF884</gtr:id><gtr:title>Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa72ccebe439d7b1632d0e5d55203218"><gtr:id>aa72ccebe439d7b1632d0e5d55203218</gtr:id><gtr:otherNames>Ohkuma T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>5aa8eb5e68d5b1.24090533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2071490-D02B-4E29-9D51-1DED56AC77A9</gtr:id><gtr:title>Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/698193b173cb0d9b16b5497932c83565"><gtr:id>698193b173cb0d9b16b5497932c83565</gtr:id><gtr:otherNames>B?hm M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5aa8eb5f80dee1.86104194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B9DAEBB-409B-48AE-8BA9-3D809C9775B0</gtr:id><gtr:title>Evidence for contemporary arterial stiffening in obese children and adolescents using pulse wave velocity: A systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c7cfa298e7790ad8887a84abda3d971"><gtr:id>9c7cfa298e7790ad8887a84abda3d971</gtr:id><gtr:otherNames>Hudson LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>56dfff67283451.39761753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAFC5149-E647-4478-8A1E-4476A6CB41DE</gtr:id><gtr:title>Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus: The ADVANCE-ON Study.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa72ccebe439d7b1632d0e5d55203218"><gtr:id>aa72ccebe439d7b1632d0e5d55203218</gtr:id><gtr:otherNames>Ohkuma T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa8eb5f1ed678.87442969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>330821BE-C7CC-45B7-8D98-526D20DBD902</gtr:id><gtr:title>High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52012becf6476de385e0b6dd02020814"><gtr:id>52012becf6476de385e0b6dd02020814</gtr:id><gtr:otherNames>Tomaszewski M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>54639067edf367.62729367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CCB89E5-6210-4690-A197-E930362587F8</gtr:id><gtr:title>International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61ddbbd5c373adf86f164aa828a4ae63"><gtr:id>61ddbbd5c373adf86f164aa828a4ae63</gtr:id><gtr:otherNames>Schlaich MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>pm_23638_28_24021387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D392DA8-0315-44E2-A828-C586E71FDDEA</gtr:id><gtr:title>Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular interventions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52bf35f1ee5f77d89ab83217e2e38b35"><gtr:id>52bf35f1ee5f77d89ab83217e2e38b35</gtr:id><gtr:otherNames>Myat A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1941-7640</gtr:issn><gtr:outcomeId>pm_23638_28_23591420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2925E1FD-094B-41DD-AE3B-6FD860880547</gtr:id><gtr:title>Patient self-monitoring of blood pressure and self-titration of medication in primary care: the TASMINH2 trial qualitative study of health professionals' experiences.</gtr:title><gtr:parentPublicationTitle>The British journal of general practice : the journal of the Royal College of General Practitioners</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b57fb58330be27c2843983f1dbfd0d41"><gtr:id>b57fb58330be27c2843983f1dbfd0d41</gtr:id><gtr:otherNames>Jones MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-1643</gtr:issn><gtr:outcomeId>pm_23638_28_23735408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B7DAFDE-E9B5-49B9-94A1-FD1900FA8884</gtr:id><gtr:title>Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci&amp;oacute;n Card&amp;iacute;aca y Electrofisiolog&amp;iacute;a (SOLEACE).</gtr:title><gtr:parentPublicationTitle>European heart journal. Cardiovascular pharmacotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb84f4ac18942d2d2008bdc3eaef089f"><gtr:id>cb84f4ac18942d2d2008bdc3eaef089f</gtr:id><gtr:otherNames>Lip GYH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa8eb606f9a12.41831030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25ED1F30-EB76-480F-849A-B4A37EA75D68</gtr:id><gtr:title>Expertise: no longer a sine qua non for guideline authors?</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3efb71d61e7d20b4d24266cc10f460ea"><gtr:id>3efb71d61e7d20b4d24266cc10f460ea</gtr:id><gtr:otherNames>Messerli FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>5aa8eb6114bfd9.83453877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A702E2F1-9A52-438E-BB66-5A00F282DD23</gtr:id><gtr:title>Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d0d2c3674731421901f51e107db5381"><gtr:id>8d0d2c3674731421901f51e107db5381</gtr:id><gtr:otherNames>Kaambwa B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn><gtr:outcomeId>pm_23638_28_23990660</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13090</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>